Drugs / LV-NYESO TCR/sr39TK PBSC
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03240861 | Jul 2017 → Oct 2023 | high grade malignant neoplasm, sarcoma | Jonsson Comprehensive Cancer Center | Terminated | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | LV-NYESO TCR/sr39TK PBSC | “Patients receive LV-NYESO TCR/sr39TK PBSC IV on day 0” NCT03240861 ↗ |
| Route | Intravenous | “Patients receive LV-NYESO TCR/sr39TK PBSC IV on day 0” NCT03240861 ↗ |